{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:15:39Z","timestamp":1791375339393,"version":"4.3.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The first long-acting injectable antiretroviral, cabotegravir\/rilpivirine (LA-CAB\/RPV), was approved by the Food and Drug Administration (FDA) in January 2021 for persons with human immunodeficiency virus (HIV) suppressed on their current regimen. Body mass index (BMI) \u226530\u2005kg\/m2 has been identified as a risk factor for virologic failure; however, data are limited due to small sample sizes. The aim of this study was to evaluate the impact of BMI on the efficacy of LA-CAB\/RPV in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, multicenter cohort study was conducted from 22 January 2021 to 15 February 2023 in individuals who received LA-CAB\/RPV every 4 (Q4w) or 8 weeks (Q8w). Individuals included were virologically suppressed on their current regimen, received at least 1 dose of LA-CAB\/RPV, and had a follow-up viral load post initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 374 individuals across 5 centers were included, with a BMI \u226530\u2005kg\/m2 in 148 (39.5%) individuals. Most individuals received a Q8w (68%) regimen, and the incidence of viral load \u226550\u2005copies\/mL was similar between those with BMI \u226530\u2005kg\/m2 (12%) as compared to those with BMI &amp;lt;30\u2005kg\/m2 (9%) (incidence rate ratio [IRR] 1.31; 95% confidence interval [CI]: .69\u20132.46, P = .4). Confirmed virologic failure occurred in 0.8% of individuals overall, with 2 of the 3 cases occurring in those with BMI \u226530\u2005kg\/m2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The data from this real-world cohort demonstrates no difference in virologic outcomes for individuals with BMI \u226530\u2005kg\/m2 as compared to those with BMI &amp;lt;30\u2005kg\/m2 suggesting that higher BMI alone should not preclude use of LA-CAB\/RPV in eligible individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciae579","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T23:23:59Z","timestamp":1732663439000},"page":"67-74","source":"Crossref","is-referenced-by-count":14,"title":["Real World Virologic Outcomes in Patients With Elevated Body Mass Index Receiving Long Acting Cabotegravir\/Rilpivirine"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5590-2736","authenticated-orcid":false,"given":"Christina","family":"Maguire","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Penn Presbyterian Medical Center , Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2563-6958","authenticated-orcid":false,"given":"Kaitlyn","family":"Rueve","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Indiana University Health , Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Farmer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Indiana University Health , Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Huesgen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Indiana University Health , Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoneta","family":"Karaj","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Perelman School of Medicine , Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-0176","authenticated-orcid":false,"given":"Amanda","family":"Binkley","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Penn Presbyterian Medical Center , Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8537-7103","authenticated-orcid":false,"given":"Karam","family":"Mounzer","sequence":"additional","affiliation":[{"name":"Philadelphia FIGHT Community Health Centers , Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Brizzi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Cincinnati Medical Center , Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Chary","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Hospital of the University of Pennsylvania , Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sung","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Hospital of the University of Pennsylvania , Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Graziani","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Hospital of the University of Pennsylvania , Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hiserodt","sequence":"additional","affiliation":[{"name":"Philadelphia FIGHT Community Health Centers , Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5702-5848","authenticated-orcid":false,"given":"Jillian","family":"Baron","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Pennsylvania Perelman School of Medicine , Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Koenig","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Pennsylvania Perelman School of Medicine , Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4225-8336","authenticated-orcid":false,"given":"William R","family":"Short","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Pennsylvania Perelman School of Medicine , Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2025080104320793400_ciae579-B1"},{"key":"2025080104320793400_ciae579-B2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS"},{"key":"2025080104320793400_ciae579-B3","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from atlas-2 m, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025080104320793400_ciae579-B4","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2025080104320793400_ciae579-B5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for the treatment and prevention of HIV infection in adults: 2022 Recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2025080104320793400_ciae579-B6","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"2025080104320793400_ciae579-B7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-021-01005-1","article-title":"Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine","volume":"60","author":"Hodge","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2025080104320793400_ciae579-B8","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","article-title":"Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (\u00c9CLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial","volume":"4","author":"Markowitz","year":"2017","journal-title":"Lancet HIV"},{"key":"2025080104320793400_ciae579-B9","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1111\/bcp.15439","article-title":"Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects","volume":"88","author":"Han","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"Supplement 2","key":"2025080104320793400_ciae579-B10","doi-asserted-by":"publisher","first-page":"S865","DOI":"10.1093\/ofid\/ofz360.2173","article-title":"Pharmacokinetics of cabotegravir and rilpivirine long-acting injectables in HIV-infected individuals through 48 weeks in the FLAIR and ATLAS phase 3 studies [poster 2495]","volume":"6","author":"Patel","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025080104320793400_ciae579-B11","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1111\/bcp.15439","article-title":"Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects","volume":"88","author":"Han","year":"2022","journal-title":"Brit J Clinical Pharma"},{"key":"2025080104320793400_ciae579-B12","doi-asserted-by":"crossref","first-page":"e1081","DOI":"10.1097\/MD.0000000000001081","article-title":"Obesity among HIV-infected adults receiving medical care in the United States: data from the cross-sectional medical monitoring project and national health and nutrition examination survey","volume":"94","author":"Thompson-Paul","year":"2015","journal-title":"Medicine"},{"key":"2025080104320793400_ciae579-B13","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988","edition":"2nd edn"},{"key":"2025080104320793400_ciae579-B14","doi-asserted-by":"crossref","DOI":"10.1201\/9780429055713","volume-title":"Analysis of incidence rates","author":"Cummings","year":"2019"},{"key":"2025080104320793400_ciae579-B15","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2025080104320793400_ciae579-B16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11904-020-00483-5","article-title":"Obesity and weight gain in persons with HIV","volume":"17","author":"Bailin","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"Supplement_2","key":"2025080104320793400_ciae579-B17","doi-asserted-by":"crossref","first-page":"ofad500","DOI":"10.1093\/ofid\/ofad500.1443","article-title":"1608. Real-world effectiveness of long-acting cabotegravir + rilpivirine in virologically suppressed treatment-experienced individuals: two years of data from the OPERA\u00ae cohort","volume":"10","author":"Sension","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025080104320793400_ciae579-B18","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025080104320793400_ciae579-B19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/QAI.0b013e31819e721b","article-title":"Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay","volume":"51","author":"Lima","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025080104320793400_ciae579-B20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1086\/595707","article-title":"Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor monitor","volume":"48","author":"Gatanaga","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025080104320793400_ciae579-B21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/QAI.0b013e3181d01d1d","article-title":"Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep\/COBAS TaQMAN HIV-1 version 1.0 viral load test","volume":"54","author":"Willig","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025080104320793400_ciae579-B22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/QAD.0000000000000544","article-title":"Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients","volume":"29","author":"Antiretroviral Therapy Cohort Collaboration (ART-CC)","year":"2015","journal-title":"AIDS"},{"key":"2025080104320793400_ciae579-B23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3851\/IMP2815","article-title":"Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV cohort study","volume":"20","author":"Boillat-Blanco","year":"2014","journal-title":"Antivir Ther"},{"key":"2025080104320793400_ciae579-B24","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/cit529","article-title":"Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation","volume":"57","author":"Laprise","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025080104320793400_ciae579-B25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral drug resistance in HIV-1\u2013infected patients experiencing persistent low-level viremia during first-line therapy","volume":"204","author":"Taiwo","year":"2011","journal-title":"J Infect Dis"},{"key":"2025080104320793400_ciae579-B26","author":"HIV Surveillance Supplemental Report"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae579\/60836943\/ciae579.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/1\/67\/60836943\/ciae579.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/1\/67\/60836943\/ciae579.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T08:32:37Z","timestamp":1754037157000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/1\/67\/7909880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,27]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae579","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,15]]},"published":{"date-parts":[[2024,11,27]]}}}